Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing the metal of ERCC2 in predicting the response to platinum-based therapy.

Cancer discovery - 1 Oct 2014

Turchi John J, Woods Derek S, VanderVere-Carozza Pamela

Abstract excerpt

DNA repair has been shown to affect the cellular response to platinum-based therapy in a variety of cancers; however, translating this knowledge to the clinic has proven difficult and yielded mixed results. In this issue of Cancer Discovery, Van Allen and colleagues have analyzed responders and n...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Drug Resistance, Neoplasm
Share to ERCC2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Urologic Neoplasms

Share to Urothelium

Share to Xeroderma Pigmentosum Group D Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 25274682
DOI: 10.1158/2159-8290.CD-14-0893
PMCID: PMC4185394

Genes

ERCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25274682-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing the metal of ERCC2 in predicting the response to platinum-based therapy.PMID 25274682Read ↗

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerSemantic proximity Read ↗

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataSemantic proximity Read ↗

XPA tumor variants lead to defects in NER that sensitize cells to cisplatinSemantic proximity Read ↗

Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSemantic proximity Read ↗

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial CancerSemantic proximity Read ↗

A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor ResistanceSemantic proximity Read ↗

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Semantic proximity Read ↗

ERCC1 and Clinical Resistance to Platinum-Based TherapySemantic proximity Read ↗

Platinum Resistance: The Role of DNA Repair PathwaysSemantic proximity Read ↗

Genomic characterization of response to chemoradiation in urothelial bladder cancer.Semantic proximity Read ↗

Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.